Jack V. Talley is a pharmaceutical management professional with more than 30 years of experience in the industry. He has taken three companies successfully public. He has been responsible for more than 20 equity issuances in both the private and public sectors raising in aggregate in excess of $100 million. Two of the three companies he has taken public have been successfully sold, the third is still independent. He has been responsible for numerous business development transactions and has secured product approvals in both Europe and the United States for a wide variety of investigational drugs. Most recently he was the President, CEO and a member of the Board of Directors for Alissa Pharma, LLC a privately held company focused on antibody directed isotopes for various forms of cancer. Previously he was the CEO, President and a Director of Actinium Pharmaceuticals, Inc. (API) which he took public. Mr. Talley joined API from the position of President, Chief Executive Officer and a Director at EpiCept Corporation which he also took public. Prior to EpiCept, Mr. Talley was the Chief Executive Officer of Consensus Pharmaceuticals, Inc., a biotechnology drug discovery start-up company that developed a proprietary peptide-based combinatorial library screening process. Prior to joining Consensus, Mr. Talley led Penwest Ltd.’s efforts in its IPO spin-off of its subsidiary Penwest Pharmaceuticals Co. in 1998 and served as President and Chief Operating Officer of Penwest Pharmaceuticals. Penwest was eventually acquired by Endo. Mr. Talley led the alliance between Penwest and Endo. Mr. Talley started his career at Sterling Drug Inc., where he was responsible for all U.S. marketing activities for prescription drugs when the company was merged with Sanofi, he launched various new pharmaceutical products and participated in the 1988 acquisition of Sterling Drug by Eastman Kodak Co. Mr. Talley received his B.S. in Chemistry from the University of Connecticut and completed coursework towards an M.B.A. in Marketing from New York University, Graduate School of Business.
biotechnology drug discovery